| Diabetes Mellitus, Non-Insulin-Dependent
Brenzavvy vs Victoza
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Brenzavvy vs Victoza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVictoza has a higher rate of injection site reactions vs Brenzavvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Victoza but not Brenzavvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brenzavvy
Victoza
At A Glance
Oral
Daily
SGLT2 inhibitor
SC injection
Daily
GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 20 mg orally once daily in the morning, with or without food; do not crush or chew the tablet; withhold for at least 3 days prior to major surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases (Adults) Start at 0.6 mg SC once daily for one week, then increase to 1.2 mg once daily; if additional glycemic control is required, increase to 1.8 mg once daily (maximum) after at least one week at 1.2 mg.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric >= 10 years) Start at 0.6 mg SC once daily; increase in 0.6 mg increments after at least one week on the current dose; maximum recommended dose is 1.8 mg once daily.
Contraindications
- Hypersensitivity to bexagliflozin or any excipient in BRENZAVVY
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to liraglutide or any excipient in VICTOZA
Adverse Reactions
Most common (>=2%) Increased urination, urinary tract infection, female genital mycotic infections, thirst, vaginal pruritus, male genital mycotic infection, hypoglycemia
Serious Diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, sepsis, fractures
Most common (>=5%) Nausea, diarrhea, headache, nasopharyngitis, vomiting, decreased appetite, dyspepsia, upper respiratory tract infection, constipation, back pain
Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, dehydration, elevations of liver enzymes, hyperbilirubinemia, cholestasis, cholecystitis, cholelithiasis, hepatitis, angioedema, anaphylactic reactions, pruritus, medullary thyroid carcinoma, dysgeusia, dizziness, dysesthesia, pulmonary aspiration, acute renal failure, increased serum creatinine, cutaneous amyloidosis, alopecia
Pharmacology
Bexagliflozin is an SGLT2 inhibitor that blocks renal reabsorption of filtered glucose in the proximal tubule, lowering the renal threshold for glucose and increasing urinary glucose excretion to reduce blood glucose in adults with type 2 diabetes mellitus.
GLP-1 receptor agonist; liraglutide is an acylated human GLP-1 analog (97% amino acid sequence homology to endogenous human GLP-1(7-37)) that stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brenzavvy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Victoza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Brenzavvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Victoza
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Brenzavvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Victoza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brenzavvy.
No savings programs available for Victoza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrenzavvyView full Brenzavvy profile
VictozaView full Victoza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.